Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors

Background: Testicular cancer survivors (TCS) are at significantly increased risk for cardiovascular disease (CVD), with metabolic syndrome (MetS) an established risk factor. No study has addressed clinical and genetic MetS risk factors in North American TCS. Patients and Methods:TCS were aged <55 years at diagnosis and received first-line chemotherapy. Patients underwent physical examination, and had lipid panels, testosterone, and soluble cell adhesion molecule-1 (sICAM-1) evaluated. A single nucleotide polymorphism in rs523349 (5-α-reductase gene,SRD5A2), recently implicated in MetS risk, was genotyped. Using standard criteria, MetS was defined as ≥3 of the following: hypertension, abdominal obesity, hypertriglyceridemia, decreased high-density lipoprotein (HDL) cholesterol level, and diabetes. Matched controls were derived from the National Health and Nutrition Examination Survey.Results:We evaluated 486 TCS (median age, 38.1 years). TCS had a higher prevalence of hypertension versus controls (43.2% vs 30.7%;P<.001) but were less likely to have decreased HDL levels (23.7% vs 34.8%;P<.001) or abdominal obesity (28.2% vs 40.1%;P<.001). Overall MetS frequency was similar in TCS and controls (21.0% vs 22.4%;P=.59), did not differ by treatment (P=.20), and was not related to rs523349 (P=.61). For other CVD risk factors, TCS were significantly more likely to have elevated low-density lipoprotein (LDL) cholesterol levels (17.7% vs 9.3%;P<.001), total cholesterol levels (26.3% vs 11.1%;P<.001), and body mass index ≥25 kg/m2(75.1% vs 69.1%;P=.04). On multivariate analysis, age at evaluation (P<.001), testosterone level ≤3.0 ng/mL (odds ratio [OR], 2.06;P=.005), and elevated sICAM-1 level (ORhighest vs lowest quartile, 3.58;P=.001) were significantly associated with MetS.Conclusions and Recommendations:Metabolic abnormalities in TCS are characterized by hypertension and increased LDL and total cholesterol levels but lower rates of decreased HDL levels and abdominal obesity, signifying possible shifts in fat distribution and fat metabolism. These changes are accompanied by hypogonadism and inflammation. TCS have a high prevalence of CVD risk factors that may not be entirely captured by standard MetS criteria. Cancer treatment-associated MetS requires further characterization.

Journal of the National Comprehensive Cancer Network : JNCCN. 2018 Mar [Epub]

Mohammad Abu Zaid, Wambui G Gathirua-Mwangi, Chunkit Fung, Patrick O Monahan, Omar El-Charif, Annalynn M Williams, Darren R Feldman, Robert J Hamilton, David J Vaughn, Clair J Beard, Ryan Cook, Sandra K Althouse, Shirin Ardeshir-Rouhani-Fard, Paul C Dinh, Howard D Sesso, Lawrence H Einhorn, Sophie D Fossa, Lois B Travis, Platinum Study Group

From Indiana University, Melvin and Bren Simon Cancer Center, and Indiana University School of Nursing, Indianapolis, Indiana; University of Rochester Medical Center, James P. Wilmot Cancer Institute, Rochester, New York; Department of Medicine, University of Chicago, Chicago, Illinois; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York; Division of Urology, Princess Margaret Cancer Centre, Toronto, Ontario; Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Radiation Oncology, Dana-Farber Cancer Institute, and Divisions of Preventive Medicine and Aging, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; and Department of Oncology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe